San Francisco, California-- (Newsfile Corp. - January 30, 2025) - Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) faces a securities fraud class action after shares of the company plunged $84.59 on Oct ...

Analyst Chris Schott from J.P. Morgan maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.8 billion, has been navigating a complex ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $945.56, a high ...

Beyond the current product portfolio, Regeneron has an exciting new product pipeline with over 35 candidates in various stages of development, including a novel treatment for treating severe food ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target cut by research analysts at Piper Sandler from $1,195.00 to $1,013.00 in a report issued on Monday,Benzinga reports. The ...

The company currently has 13 approved or authorized medicines and about 40 product candidates in clinical development across various therapeutic areas. Regeneron Pharmaceuticals Inc.’s (NASDAQ ...

Regeneron Canada Company today officially opened its first headquarters that will allow it to better serve the needs of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...